Originally developed by Novo Nordisk to treat type-2 diabetes, semaglutide, delivered in an injection, has gained global attention for its weight-loss benefits
The reviews approach allows for a broad, "state-of-the-union" summary of the evidence, particularly regarding the two most controversial areas in clinical conversation, thyroid and pancreatic cancer
GLP-1 receptor agonists are medications that imitate the effects of glucagon-like peptide-1, a hormone released after eating
The metabolomic approach to the intestinal microbiome suggests that the reduced SCFA levels, caused by the lower abundance of Firmicutes, may have an effect on the immune system
They discuss the use of glp-1s in functional medicine, specifically semi-glutides, for weight loss and metabolic health protocols
In response, pancreatic beta cells secrete insulin that promotes glucose absorption primarily to the liver and skeletal muscles, where it is converted to glycogen